QUARTERLY REPORT 3

September 2017 – May 2018

Diamyd Medical AB (publ), Fiscal year 2017/2018

Two drugs in clinical development

Diamyd® to preserve the endogenous insulin production in autoimmune diabetes

Remygen™ to stimulate the regeneration of insulin-producing cells in autoimmune diabetes and type 2 diabetes

Diamyd Medical's B-share is traded on Nasdaq First North under the ticker DMYD B. Further information is available on the Company's website: https://www.diamyd.com

Diamyd Medical AB (publ)
Kungsgatan 29 • SE-111 56 Stockholm • Phone 08-661 00 26
www.diamyd.com • info@diamyd.com

September 1, 2017 – May 31, 2018

- Net result amounted to MSEK -32.5 (-19.0), of which the third quarter constituted of MSEK -12,6 (-8.3). The change compared with the previous year relates to the DIAGNODE-2 trial that started this financial year.
- Result per share, before and after dilution, amounted to SEK -0.6 (-0.6), of which the third quarter constituted of SEK -0.2 (-0.3)
- Cash flow from operating activities amounted to MSEK -32.6 (-16.0) of which the third quarter constituted of MSEK -9.6 (-5.4)
- Liquid assets and short-term investments amounted as of May 31 to MSEK 52.8 (12.2)

Significant events during the third quarter, March 1, 2018 – May 31, 2018

- Finalizing of Diamyd® drug substance is planned to coincide with DIAGNODE-2 results
- Swedish MPA approved an additional injection of Diamyd® in ongoing clinical pilot trial
- Results supporting intralymphatic administration of Diamyd® was published in the Journal of Diabetes Research
- Enrollment milestone 50% was reached in Diamyd Medical's European Phase II trial
- Results showing GABA's relevance for diabetes were published in eBioMedicine
- Diamyd® intranodally continued to show stronger results than when administered subcutaneously

Significant events after the reporting period

- Remygen™ for regeneration of insulin-producing cells was approved for clinical trials

"With two drugs in clinical development that complement and strengthen each other, the likelihood increases of making meaningful differences for those who live with diabetes."

Ulf Hannelius, CEO

CEO comments

Dear Shareholders and Readers,

Two weeks ago, Diamyd Medical had another drug enter clinical development phase, when the Swedish Medical Products Agency approved our GABA-based Remygen™ for clinical trials. I would like to clearly highlight the importance of having two drugs – Diamyd® and Remygen™ – in clinical development phase. Both of our clinical development drugs focus on the underlying disease mechanisms in diabetes with the goal of slowing, stopping and ultimately reversing the progression of the disease. Intralymphatic administration of Diamyd® continues to show strong results in the ongoing clinical program, and Remygen™ can cite a large and growing base of research indicating the potential of GABA, the active component in Remygen™, in diabetes.

Our manufacture of GABA clinical development drug began in order to maintain control of product development and rights associated with GABA. Remygen™, which is the result of this venture and our own formulation of GABA, was approved in June for use in a clinical trial, ReGenerate-1, which will be conducted by Uppsala University Hospital. The trial will evaluate both the safety and the effects of Remygen™ in stimulating growth of insulin-producing cells in patients who have had type 1 diabetes for more than five years. In parallel with this trial, a placebo-controlled trial is ongoing at the University of Alabama at Birmingham, in the United States, in which GABA is being evaluated as a food supplement in patients with newly diagnosed type 1 diabetes. Together, ReGenerate-1 and the Alabama trial constitute great value for Diamyd Medical, providing us with the basis for decisions on how a GABA-based medical treatment can be optimized and brought to market.

Last year, through the successful rights issue, we gained the trust from our shareholders to take the intralymphatic administration of Diamyd® into clinical phase IIb. Today, one year later, the open trial DIAGNODE-1 has generated results and the placebo-controlled European DIAGNODE-2 trial is in full swing with more than 50 of the estimated 80 patients included in the trial. The immunological results from DIAGNODE-1, the investigator-initiated pilot trial that paved the way for DIAGNODE-2, were published in May. In the May-publication it is reported that patients who have been treated with intralymphatic administration show a considerably stronger immune response, and earlier it has been shown that the patients' need of external insulin, as well as blood sugar levels are significantly improved compared with subcutaneous administration. We have the technique of administering Diamyd® intralymphatically to type 1 diabetes patent pending and our patent application also covers other antigen-specific treatments and autoimmune diseases. With the results we have today, this certainly looks like a promising technique for both type 1 diabetes and hopefully for other autoimmune diseases.

In September, 15-month clinical results from all patients in the DIAGNODE-1 pilot trial will be presented. An important milestone that gives us a complete picture of how the clinical course has evolved over the same period of time (15 months) as patients will be followed up in DIAGNODE-2.

Together with ongoing business development and clinical trials with both Diamyd® and Remygen™, we are in an intensive period. With two drugs in clinical development that complement and strengthen each other, the likelihood increases of making meaningful differences for those who live with diabetes, and I look forward to reporting further progress in the coming months.

Stockholm, June 27, 2018

Ulf Hannelius,

President and CEO

Two drugs in clinical development



Diamyd® and Remygen™ are drugs in clinical development that focus on the underlying disease mechanisms of diabetes; the dysfunction and loss of insulin-producing beta cells in the pancreas.

Diamyd® is an antigen-specific immunotherapy for the treatment of autoimmune diabetes (type 1 diabetes).

Clinical data indicate the potential of the diabetes vaccine Diamyd® to halt or stop the autoimmune destruction of insulin-producing beta cells. The effect is achieved by antigen-specific reprogramming of immune cells by administration of low doses of Diamyd® in superficial lymph nodes.

By maintaining the endogenous insulin production, Diamyd® has the potential to significantly reduce the complications of autoimmune diabetes.

Intralymphatic treatment with Diamyd® is now being investigated in clinical phase IIb (DIAGNODE-2) for the treatment of type 1 diabetes, with the aim of confirming a previously demonstrated clinical effect from a pilot trial in type 1 diabetes patients (DIAGNODE-1).

Remygen™ is an oral regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 diabetes.

Preclinical data indicate GABA's potential to stimulate growth and function of insulin-producing beta cells. The effect is achieved primarily by increasing the levels of GABA in the blood and thus activating GABA receptors that affect the function and growth of insulin-producing cells in the pancreas.

By stimulating the growth of insulin-producing cells, Remygen™ has the potential to reverse the disease progression in autoimmune and type 2 diabetes.

Remygen™ is now being investigated in clinical phase Ib /IIa where clinical efficacy is evaluated with the aim of optimizing treatment ahead of registration-based trials.

Significant events during the third quarter

March 1, 2017 – May 31, 2018

Finalizing of Diamyd® drug substance is planned to coincide with DIAGNODE-2 results

Diamyd Medical and the Company's manufacturer of recombinant GAD, the active component of the diabetes vaccine Diamyd®, are working on an updated plan for the new batches of GAD that the Company ordered last year for use in late clinical trials and possible early market launch, to be finalized approximately at the same time as results from the DIAGNODE-2 trial, which also optimizes the shelf life of the drug substance.

Swedish MPA approved an additional injection of Diamyd® in ongoing clinical pilot trial

The Swedish MPA approved an extension of DIAGNODE-1, an open label clinical pilot trial in which the diabetes vaccine Diamyd® is given directly into the lymph node. The extension refers to three adult patients included in the trial who will be offered a fourth injection Diamyd®.

Results supporting intralymphatic administration of Diamyd® was published in the Journal of Diabetes Research

New results with the diabetes vaccine Diamyd®, comparing the immune responses after intralymphatic administration with immune responses after administering the vaccine subcutaneously, were published in the Journal of Diabetes Research. The article, authored by researchers at Linköping University, describes that a more favorable immune response is achieved after intralymphatic treatment which may correlate with clinical effect. The results have generated patents filed by Diamyd Medical.

Enrollment milestone 50% was reached in Diamyd Medical's European Phase II trial

The Company announced that half of the patients, 40 out of 80, had been included in the European Phase II trial DIAGNODE-2.

Results showing GABA's relevance for diabetes were published in eBioMedicine

Diamyd Medical holds, in collaboration with Professor Bryndis Birnir at Uppsala University, patent pending new GABA results. The results, supporting GABA's role as a therapeutic important signal substance in the insulin producing beta cells and in immune cells from healthy humans as well as from patients with type 1 and type 2 diabetes, were published in the scientific journal eBioMedicine.

Diamyd® intranodally continued to show stronger results than when administered subcutanously

A preliminary 15-month interim report from EDCR IIa, an investigator initiated pilot trial where the diabetes vaccine Diamyd® is administered subcutaneously in combination with etanercept and vitamin D showed, when all 20 patients had been followed for fifteen months, that the treatment is safe and tolerable. No serious side effects had been reported. Results pertaining to the patients' own insulin production, HbA1c and external insulin requirements were, however, weaker in EDCR IIa than from the ongoing DIAGNODE-1 trial where the diabetes vaccine is administered directly into the lymph node.

A sixth interim report from the investigator initiated DIAGNODE-1 trial, showed a continued positive clinical course in terms the patients' own ability to produce insulin as well as long-term blood sugar and insulin dose when nine patients had been followed for 15 months.

Significant events after the reporting period

Diamyd Medical's Remygen™ for regeneration of insulin-producing cells was approved for clinical trials

The Swedish Medical Products Agency approved the initiation of the clinical Phase I/II trial ReGenerate-1, with Diamyd Medical's patent-pending study drug Remygen™. In addition to evaluating the safety of the study drug, the trial will investigate Remygen's ability to regenerate insulin-producing beta cells in patients with diabetes who have little or no endogenous insulin production.

Clinical trials

Type 1 diabetes is a devastating disease which requires daily treatment with insulin to sustain life. The importance of finding a drug that improves the prospects for diabetic patients is of utmost importance. The effect of intralymphatic administration of Diamyd®, an antigen-specific immunotherapy aimed at stopping the immune system's attack on insulin-producing beta cells in autoimmune diabetes, is evaluated in the phase IIb trial DIAGNODE-2. Remygen™, which aims to stimulate the growth of beta cells in patients with diabetes, will be evaluated in patients for the first time in 2018. In addition to these, Diamyd® is evaluated in various combinations and modes of administration in ongoing investigator-initiated trials.

Trials with Diamyd® intralymphatically

- **DIAGNODE -2 – DIAMYD® IN LYMPH NODES IN COMBINATION WITH VITAMIN D**
  DIAGNODE-2 is a follow-up double-blind randomized trial where Diamyd® is administered directly into lymph nodes in combination with treatment with vitamin D. The trial encompasses approximately 80 patients from Sweden, the Czech Republic and Spain, aged 12–24 years that have recently been diagnosed with type 1 diabetes and will continue for a total of 15 months. The trial is a follow up of DIAGNODE-1. The aim of the trial is to evaluate the patients' remaining insulin producing capacity. Coordinating Investigator is Professor Johnny Ludvigsson at Linköping University. Diamyd Medical is the Sponsor of the trial.

- **DIAGNODE -1 – DIAMYD® IN LYMPH NODES IN COMBINATION WITH VITAMIN D**
  An open label trial, where Diamyd® is administered directly into lymph nodes in combination with treatment with vitamin D. The trial comprises twelve patients between the ages of 12 and 30 newly diagnosed with type 1 diabetes and will continue for a total of 30 months. The trial was fully recruited in June 2017. The aim of the trial is to evaluate the safety of the combination treatment and the effect on the immune system and the patients' insulin producing capacity. The trial is led by Professor Johnny Ludvigsson at Linköping University, Sweden.

Trials with Remygen™ and GABA/Diamyd®

- **REGENERATE-1 – REMYGEN™**
  ReGenerate-1 is an open-label, investigator-initiated clinical trial with Remygen™. The trial will include patients aged 18-50 who have had type 1 diabetes for more than five years with low to non-existing insulin production. The primary aim of the trial is to in a smaller dose escalation section evaluate the safety of Remygen™. The main trial will also evaluate whether the insulin-producing cells can be regenerated using Remygen™. The trial is led by Professor Per-Ola Carlsson at Uppsala University. The trial is planned to start in 2018.

- **GABA/ DIAMYD® – COMBINING DIAMYD® WITH GABA**
  A placebo-controlled trial, where Diamyd® is given subcutaneously and being tested in combination with GABA. In accordance with agreement with Jansen Research & Development and JDRF the trial has expanded to comprise 95 patients between the ages of 4 and 18 recently diagnosed with type 1 diabetes. The trial will continue for a total of 12 months. The aim of the combination treatment is to preserve the body's residual capacity to produce insulin. The trial is led by Professor Kenneth McCormick at the University of Alabama at Birmingham, USA.

Other ongoing trials with Diamyd®

- **EDCR IIa – COMBINING DIAMYD® WITH ETANERCEPT AND VITAMIN D**
  An open label trial, where Diamyd® is given subcutaneously and being tested in combination with etanercept and vitamin D. The trial comprises 20 patients between the ages of 8 and 18 who have been newly diagnosed with type 1 diabetes and will continue for a total of 30 months. The aim of the trial is to evaluate the safety of the combination treatment and the effect on the immune system and the patients' insulin producing capacity. The trial is led by Professor Johnny Ludvigsson at Linköping University, Sweden.

- **DiAPREV-IT 2 – COMBINING DIAMYD® WITH VITAMIN D**
  A placebo-controlled trial, where Diamyd® is given subcutaneously and being tested in combination with vitamin D in children at high risk of developing type 1 diabetes, meaning that they have been found to have an ongoing autoimmune process but do not yet have any clinical symptoms of diabetes. The trial includes 26 children. The aim of the trial is to evaluate whether Diamyd® can delay or prevent the participants from presenting with type 1 diabetes. The trial is led by Dr. Helena Elding Larsson at Lund University, Sweden.

Key figures

	3 months Mar-May 2018	3 months Mar-May 2017	9 months Sep-May 2017/18	9 months Sep-May 2016/17	12 months Sep-Aug 2016/17
Research and development costs, MSEK	-8.5	-5.1	-21.2	-9.8	-12.9
Solidity, %	84	40	84	40	88
Result per share, before and after dilution, SEK	-0.2	-0.3	-0.6	-0.6	-0.7
Liquidity and short-term investments per share, Before and after dilution, SEK	0.9	0.4	0.9	0.4	1.5
Equity per share, before and after dilution, SEK	1.0	0.3	1.0	0.3	1.5
Cash flow per share, before and after dilution, SEK	0.0	-0.3	-0.4	-0.5	0.8
Share price per closing, SEK	4.2	4.0	4.2	4.0	3.0
Number of shares per closing	56 333 904	29 492 562	56 333 904	29 492 562	56 333 904
Average number of shares	56 333 904	29 492 562	56 333 904	29 492 562	34 783 517
Average number of employees	6	5	6	5	5

Income statement

KSEK	Note	3 months Mar-May 2018	3 months Mar-May 2018	9 months Sep-May 2017/18	9 months Sep-May 2016/17	12 months Sep-Aug 2016/17
OPERATING INCOME						
Net income		34	122	636	624	922
Other operating income		2	16	89	44	113
TOTAL OPERATING INCOME		36	137	725	667	1 035
OPERATING EXPENSES						
External research and development costs		-8 518	-5 076	-21 241	-9 791	-12 871
External patent- and license costs		-757	-487	-1 667	-1 494	-1 740
Personnel costs	1	-2 064	-1 846	-6 109	-5 126	-7 031
Other external costs	1	-1 223	-946	-3 974	-3 214	-4 658
Other operating expenses		-27	-65	-182	-125	-150
Depreciation and impairment of material and immaterial assets	2	-35	-26	-96	-79	-106
TOTAL OPERATING EXPENSES		12 624	-8 447	-33 269	-19 831	26 555
OPERATING RESULT		**-12 587**	**-8 310**	-32 543	**-19 164**	**-25 520**
Net Financial income/expense		29	10	30	129	-35
RESULT BEFORE TAXES		-12 559	-8 300	-32 514	-19 035	-25 555
Taxes		-	-	-	-	-
NET RESULT FOR THE PERIOD		**-12 559**	**-8 300**	**-32 514**	**-19 035**	**-25 555**

Balance sheet

KSEK	Note	**31 May 2018**	31 May 2017	31 Aug 2017
ASSETS				
NON-CURRENT ASSETS				
Intangible assets		519	295	268
Financial assets	2	7 305	5 450	7 305
TOTAL NON-CURRENT ASSETS		7 824	5 745	7 573
CURRENT ASSETS				
Trade receivables		37	185	147
Other receivables		1 273	1 353	692
Prepaid expenses and accrued income		2 821	278	4 508
Short term investments		20 018	-	30 031
Liquid assets		32 795	12 214	55 694
TOTAL CURRENT ASSETS		56 945	14 030	91 073
TOTAL ASSETS		**64 769**	**19 775**	**98 647**
EQUITY AND LIABILITIES				
EQUITY				
Restricted equity				
Share capital		5 714	2 991	5 714
Statutory reserve		200	200	200
Non-restricted equity				
Share premium reserve non-restricted		137 032	54 460	137 038
Profit or loss brought forward		-56 286	-30 731	-30 731
Net loss for the period		-32 514	-19 035	-25 555
TOTAL EQUITY		54 145	7 885	86 666
PROVISIONS				
Pensions and other obligations		777	777	777
Other provisions	3	1 107	1 968	1 813
TOTAL PROVISIONS		1 885	2 746	2 591
CURRENT LIABILITIES				
Trade payables		2 149	5 462	6 368
Other payables		812	702	584
Prepaid income and accrued expenses		5 778	2 980	2 438
TOTAL CURRENT LIABILITIES		8 739	9 145	9 390
TOTAL EQUITY AND LIABILITIES		**64 769**	**19 775**	98 647

Statement of cash flow

KSEK	Not	3 months Mar-May 2018	3 months Mar-May 2017	9 months Sep-May 2017/18	9 months Sep-Feb 2016/17	12 months Sep-Aug 2016/17
OPERATING ACTIVITIES						
Operating profit/loss		-12 588	-8 310	-32 543	-19 164	-25 520
Interest received		74	-2	203	0	-
Interest paid		-45	-5	-173	-5	-68
Non-cash flow items						
Depreciation		35	26	96	79	106
Other non-cash flow items		-276	-155	-706	-465	-619
CASH FLOW FROM OPERATING ACTIVITIES BEFORE CHANGES IN WORKING CAPITAL		**-12 800**	**-8 445**	**-33 124**	**-19 554**	**-26 101**
Increase (-) decrease (+) receivables		-527	-661	1 217	-261	-3 793
Increase (+) decrease (-) debts		-3 689	3 639	-651	3 839	4 085
NET CASH FLOW FROM OPERATING ACTIVITIES		**-9 638**	**-5 446**	**-32 558**	**-15 975**	**-25 808**
INVESTING ACTIVITIES						
Investment in material and immaterial assets		-178	-	-347	-	-
Investment in financial assets		-	-570	-	-997	-2 852
Investment in short term investments		10 025	0	10 013	4 999	-25 032
NET CASH FLOW FROM INVESTING ACTIVITIES		-9 846	**-571**	9 665	**4 001**	**-27 885**
FINANCING ACTIVITIES						
New issue		-	-	-	-	88 816
Issue expenses		-	-2 343	-7	-2 343	-5 858
NET CASH FLOW FROM FINANCING ACTIVITIES		-	**-2 343**	-7	**-2 343**	**-82 958**
TOTAL CASH FLOW FOR THE PERIOD		**-208**	**-8 380**	**-22 900**	**-14 316**	**29 265**
Cash and cash equivalents at beginning of period		32 587	20 555	55 695	26 397	26 397
Net foreign exchange difference		0	39	0	134	32
CASH AND CASH EQUIVALENTS AT END OF PERIOD		**32 795**	**12 214**	**32 795**	**12 214**	**55 695**

Statement of changes in equity

KSEK	Note	Share Capital	Statutory Reserve	Share premium reserve non restricted	Other non-restricted equity	Total Shareholders' equity
OPENING BALANCE SEPTEMBER 1, 2016		2 991	200	56 803	-30 732	29 263
Net result		-	-	-	-25 555	-25 555
New issue		2 772	-	91 223	-	93 945
Issue expenses		-	-	-10 987	-	-10 987
CLOSING BALANCE AUGUST 31, 2017		5 713	200	137 039	-56 287	86 666
OPENING BALANCE SEPTEMBER 1, 2017		**5 713**	**200**	**137 039**	**-56 287**	**86 666**
Net result		-	-	-	-32 514	-32 514
Issue expenses		-	-	-7	-	-7
CLOSING BALANCE MAY 31, 2018		**5 713**	**200**	**137 032**	**-88 801**	**54 145**

Notes

Accounting principles

Interim and annual reports are prepared with the application of the Annual Accounts Act and the Swedish Accounting Standards Board BFNAR 2012: 1 Annual Report and Consolidated accounts (K3).

Note 1 – Related-party transactions

During the period companies represented by immediate family members of the main owner and Board member Anders Essen-Möller were contracted as consultants. The consultancy services were attributable to IT-services. Total compensation for consultancy services and salaries to immediate family members amounted to 673 (662) KSEK. As working Board member, Anders Essen-Möller has through a company owned by Essen-Möller been compensated by KSEK 559 (631). Pricing has been set by the arm's length principle.

KSEK	Sep-May 2017/18	Sep-May 2016/18
Consultant fees and salaries to related parties	732	662
Consultant fees to Board members	559	631

Note 2 – Financial assets

Diamyd Medical owns shares in NextCell Pharma AB (corporate registration no 556965-8361) who develops stem cell therapies and also operates a stem cell bank for private family saving of stem cells. The registered office is in Huddinge, Stockholm County. As of May 31, 2018, the carrying amount was approximately MSEK 3.9. Diamyd Medical's share of the equity as well as share of the votes was as of May 31, 2018, approximately 13.8%. Diamyd Medical holds approximately 5,6% of the medical device company Companion Medical, Inc., based in San Diego, USA. Companion Medical develops technical devices for people with insulin treated diabetes. The holding is valued at cost, approximately MSEK 2.8.

Note 3 – Provisions

The amount constitutes mainly of accrued research and development costs.

Warrants

In connection with a rights issue in 2017, 852 074 warrants were issued for Series A shares and 25 989 268 warrants for Series B shares. Holders of warrants are entitled to for two (2) warrants for Series A or B shares subscribe for one (1) new share of each kind in Diamyd Medical during the period 1-30 November 2018 at issue price 4.55 SEK per new share.

Risks

Diamyd Medical's operations are associated with risks related to inter alia, drug development, commercialization, financing, intellectual property, collaborations with partners, authority decisions, agreements and key personnel. For a description of the Company's risks, please see the Annual Report for the fiscal year 2016/2017. No significant changes in the Company's risk assessment have occurred since the Annual Report was issued.

Statement

The Board of Directors and the CEO certify that the interim report gives a fair overview of the business, position and profit or loss of the Company and describes the principal risks and uncertainties that face the Company.

This report has not been reviewed by the Company's auditors.

Stockholm, June 27, 2018

Erik Nerpin
Chairman of the Board

Anders Essen-Möller
Board member

Maria-Teresa Essen-Möller
Board member

Torbjörn Bäckström
Board Member

Ulf Hannelius
President & CEO

Financial calendar

Year-End Report:	October 3, 2018
Annual Report	October 25, 2018
Annual General Meeting	November 15, 2018

About Diamyd Medical

Diamyd Medical is dedicated to finding a cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cell and medical technology.

Diamyd Medical develops the diabetes vaccine Diamyd®, for antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. Diamyd® has demonstrated good safety in studies with more than 1,000 patients as well as effect in some pre-specified subgroups. Besides the Company's own European Phase-II trial DIAGNODE-2, where the diabetes vaccine is administered directly into the lymph node, there are four investigator initiated clinical trials ongoing with Diamyd®. Diamyd Medical also develops Remygen™, an oral GABA-based study drug which in June 2018 was approved by the Swedish Medical Agency for clinical trial. An investigator-initiated placebo-controlled trial with GABA and Diamyd® in patients recently diagnosed with type 1 diabetes is ongoing at the University of Alabama at Birmingham.

Exclusive licenses for GABA and positive allosteric modulators of GABA receptors for the treatment of diabetes and inflammatory diseases constitutes alongside with the diabetes vaccine Diamyd® and Remygen™ key assets. Diamyd Medical is also one of the major shareholders in the stem cell company NextCell Pharma AB and has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA. FNCA Sweden AB is the Company's Certified Adviser.

For more information, please contact:
Ulf Hannelius, President and CEO, phone: +46 736 35 42 41
Diamyd Medical AB (publ), Kungsgatan 29, SE-111 56 Stockholm, Sweden
Phone: +46 8 661 00 26 Fax: +46 8 661 63 68 E-mail: info@diamyd.com Reg. no: 556242-3797

This information is information that Diamyd Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08.15 CET on June 27, 2018.

Note: This document has been prepared in both Swedish and English. The Swedish version shall govern in case of differences between the two documents. The document contains certain statements about the Company's operating environment and future performance. These statements should only be regarded as reflective of prevailing interpretations. No guarantees can be made that these statements are free from errors.